<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6631">
  <stage>Registered</stage>
  <submitdate>20/08/2009</submitdate>
  <approvaldate>20/08/2009</approvaldate>
  <nctid>NCT00963417</nctid>
  <trial_identification>
    <studytitle>Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02</studytitle>
    <scientifictitle>TEXT-Bone: A Substudy of the TEXT Trial to Evaluate Serial Bone Markers for Bone Remodeling, Serial Growth Factors, and Bone Mineral Density</scientifictitle>
    <utrn />
    <trialacronym>TEXT-Bone</trialacronym>
    <secondaryid>IBCSG-25A-02</secondaryid>
    <secondaryid>CDR0000637437</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - laboratory biomarker analysis
Treatment: surgery - dual x-ray absorptiometry

Active Comparator: Triptorelin plus tamoxifen - Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.

Experimental: Triptorelin plus exemestane - Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.


Other interventions: laboratory biomarker analysis
Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.

Treatment: surgery: dual x-ray absorptiometry
Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serial serum levels of C-telopeptide, osteocalcin, and bone-specific alkaline phosphatase</outcome>
      <timepoint>72 months after rnadomization to TEXT Study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serial serum levels of IGF-1 and IGFBP-3</outcome>
      <timepoint>72 months after randomization to TEXT Study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serial BMD measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA)</outcome>
      <timepoint>72 months after randomization to TEXT Study</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Patient must be eligible and enrolled in the TEXT-2 trial prior to enrolling in
             TEXT-Bone

          -  Serial bone marrow density (BMD) measurements must be taken within the same
             institution

          -  Hormone receptor positive

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

          -  Premenopausal

          -  No bone fracture in the past 6 months that, in the investigator's judgement, could be
             related to bone fragility

          -  No clinical or biochemical malabsorption syndrome, known vitamin D deficiency, active
             hyper- or hypoparathyroidism, or Paget's disease

          -  No uncontrolled thyroid disease, Cushing disease, or other pituitary diseases

          -  No other bone disease (including osteomalacia or osteogenesis imperfecta)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 6 months since prior and no concurrent bisphosphonate therapy (or other bone
             therapies such as PTH or strontium)

          -  At least 6 months since prior glucocorticoid (&gt; 5 mg prednisone or equivalent) for &gt; 1
             month

          -  At least 12 months since prior anticonvulsants</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>120</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>119</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Peter MacCallum Cancer Center - East Melbourne</hospital>
    <hospital>Box Hill Hospital - Melbourne</hospital>
    <hospital>Maroondah Hospital - Melbourne</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - East Melbourne</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Huy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Verviers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bellinzona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St.Gallen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Breast International Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Gathering information over time from bone density and laboratory tests of women
      with breast cancer treated with triptorelin and tamoxifen or exemestane may help the study of
      breast cancer in the future.

      PURPOSE: This clinical trial is studying changes in bone mineral density in women with breast
      cancer treated with triptorelin and tamoxifen or exemestane on protocol IBC SG-25-02 (TEXT).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00963417</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Olivia Pagani, MD</name>
      <address>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>